Premium – Page 2 – Endpoints News

SUBSCRIBE

‘It’s us against the world’: And George Yancopoulos wants you to know they are beating the world — big time

6 months ago

The 2018 breakdown on a chart-topping set of new drug approvals — and the 5 big things we learned from it

6 months ago

The Great Pharma Brexit? An Endpoints News snap poll finds most life sciences insiders predicting a debacle for the industry

7 months ago

Winners and losers at #ESMO18

9 months ago

Exclusive: At Hal Barron’s R&D group at GSK, consensus is out, leaders are in and watch out for an ‘intense drive’ to spur the late-stage pipeline

9 months ago

With its rep on the line, Celgene's newly-filed safety study spurs fresh worries over fate of ozanimod

9 months ago

A go-go FDA is poised to break the all-time record on new drug approvals. Is this the new standard for biopharma success?

9 months ago

Global reach: The top 25 biopharma companies in the world

10 months ago

Genentech team does some cutting-edge work on a new class of antibiotics — here's why that's important

10 months ago

The high-roller club in biopharma: Who’s paying top-dollar for upfronts? And who are the busiest players at the deal table?

10 months ago

Who are the most productive drug developers in biopharma? Our top-20 list has lots of surprises

11 months ago

Top 10 pipeline blowups, setbacks and snafus in H1 2018

12 months ago

Vant commander Ramaswamy heads back to Nasdaq with a $150M pitch — are investors ready to forgive Axovant?

Last year

12 top China VCs you need to know who are making a transpacific splash (Part 2)

Last year

RIP XTuit: Great brains, hot target and vet CEO Deborah Dunsire in charge couldn’t stop this biotech from going down

Last year

What you need to know about this record-setting biotech IPO burst as 5 more crash the party looking for $547M

Last year

The 2-trial hurdle for drug approvals is steadily losing ground. Are we devaluing the industry's R&D gold standard?

Last year

Where does the science come from? The top 20 NIH-funded institutions in 2017

Last year

The good, the bad and the ugly for the top 15 spenders in the global drug R&D business: 2018

Last year

Bristol-Myers offers some eagerly awaited Checkmate-227 results, but they're not changing medical practice -- yet

Last year

What are the top 10 corporate VCs in biopharma today? And what do they want to fund — or steer clear of?

Last year

Where the money is: Top 100 VCs investing in US biotechs during 2017

Last year

The class of 2017's winners and losers: A year of 'nonstop scientific achievements' raises troubling issues

Last year

Biopharma's top 10 overseas cash hoards. And what kind of M&A spree would $171B buy?

Last year

First page Previous page 123 Next page Last page